Compounds > bromodeoxyuridine
Page last updated: 2024-08-17

bromodeoxyuridine and Granulocytic Leukemia, Chronic

bromodeoxyuridine has been researched along with Granulocytic Leukemia, Chronic in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (40.00)18.2507
2000's2 (40.00)29.6817
2010's0 (0.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Cui, MM; Fu, PY; Huang, L; Liu, X; Wang, GC; Zhu, HZ1
Bailly, C; Dassonneville, L; Fenaux, P; Huyghe, P1
Han, MK; Horowitz, JC; Moore, BB; Thannickal, VJ; Vittal, R; Zhang, H1
Banavali, SD; Bokari, SA; Finke, D; Gopal, V; Preisler, HD1
Freund, M; Kleine, HD; Poliwoda, H; Wagner, U1

Other Studies

5 other study(ies) available for bromodeoxyuridine and Granulocytic Leukemia, Chronic

ArticleYear
MiR-199a-3p Overexpression Suppressed Cell Proliferation and Sensitized Chronic Myeloid Leukaemia Cells to Imatinib by Inhibiting mTOR Signalling.
    Acta haematologica, 2022, Volume: 145, Issue:5

    Topics: Apoptosis; Bromodeoxyuridine; Cell Line, Tumor; Cell Proliferation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Luciferases; MicroRNAs; Protein-Tyrosine Kinases; TOR Serine-Threonine Kinases

2022
Hydroxyurea-induced apoptosis in an EBV-immortalized lymphoblastoid cell line.
    Oncology research, 2004, Volume: 14, Issue:4-5

    Topics: Apoptosis; Bromodeoxyuridine; Cell Cycle; Cell Line, Transformed; Cell Membrane; Flow Cytometry; Herpesvirus 4, Human; Humans; Hydroxyurea; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Tumor Suppressor Protein p53

2004
Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment of fibrotic diseases.
    The Journal of pharmacology and experimental therapeutics, 2007, Volume: 321, Issue:1

    Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Benzamides; Bleomycin; Blotting, Western; Bromodeoxyuridine; Caspase 3; Cell Line, Tumor; Cells, Cultured; Collagen; DNA, Single-Stranded; Dose-Response Relationship, Drug; Epithelial Cells; Fibroblasts; Fibrosis; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Indicators and Reagents; Injections, Intraperitoneal; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Diseases; Mesenchymal Stem Cells; Mice; Phenotype; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction

2007
Multiparameter assessment of the cell cycle effects of bioactive and cytotoxic agents.
    Cancer research, 1992, Aug-01, Volume: 52, Issue:15

    Topics: Animals; Bone Marrow; Bromodeoxyuridine; Cell Cycle; Cell Nucleus; Cell Survival; Cells, Cultured; Chickens; Cytarabine; DNA Replication; DNA, Neoplasm; G1 Phase; G2 Phase; Interferon alpha-2; Interferon-alpha; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Mitosis; Propidium; Recombinant Proteins; S Phase; Tretinoin; Tumor Cells, Cultured

1992
Effects of tumour necrosis factor alpha on bone marrow aspirates of patients with acute myelogenous leukemia determined by flow-cytometric cell-cycle analysis.
    Journal of cancer research and clinical oncology, 1992, Volume: 118, Issue:1

    Topics: Biopsy, Needle; Blast Crisis; Bone Marrow; Bromodeoxyuridine; Cell Cycle; DNA, Neoplasm; Flow Cytometry; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Recombinant Proteins; Tumor Necrosis Factor-alpha

1992